304
Views
2
CrossRef citations to date
0
Altmetric
Review

Light Chain Cast Nephropathy in Multiple Myeloma: Prevalence, Impact and Management Challenges

, , &
Pages 173-183 | Published online: 13 May 2022

Figures & data

Box 1 Factors Precipitating Light Chain Cast Nephropathy (LCCN)

Figure 1 Pathologic findings in kidney biopsy tissue from a case of λ light chain myeloma. Hematoxylin-Eosin (A) and Masson’s trichrome (B) stains showing tubules filled with “fractured” casts surrounded by a typical granulomatous cell reaction. Direct immunofluorescence for λ light chain (C) vs κ (D) demonstrate restriction of the light chains involved in cast formation. (A and B) “fractured” cast (arrow); (AD) granuloma-like cell reaction (double arrows); glomeruli (*, asterisks). Original magnification, 200X.

Figure 1 Pathologic findings in kidney biopsy tissue from a case of λ light chain myeloma. Hematoxylin-Eosin (A) and Masson’s trichrome (B) stains showing tubules filled with “fractured” casts surrounded by a typical granulomatous cell reaction. Direct immunofluorescence for λ light chain (C) vs κ (D) demonstrate restriction of the light chains involved in cast formation. (A and B) “fractured” cast (arrow); (A–D) granuloma-like cell reaction (double arrows); glomeruli (*, asterisks). Original magnification, 200X.

Figure 2 Light Chain Cast Nephropathy: a diagnostic/therapeutic Flow Chart.

Abbreviations: AKI, acute kidney injury; MC, monoclonal; ASCT, autologous stem cell transplantation; Ig, immunoglobulin; HD, hemodialysis; HCO, high cut-off; HFR-SUPRA, hemodialysis with ultrafiltrate reinfusion (Medtronic Italia, Milan, Italy).
Figure 2 Light Chain Cast Nephropathy: a diagnostic/therapeutic Flow Chart.

Table 1 HFR-SUPRA Therapeutic Apheresis with Endogenous Reinfusion of Ultrafiltrate: Representative Comparison of Free Light Chain (FLC) Levels Before and After Each Single Session (Post-Treatment Levels are Corrected for Ultrafiltration) in 2 Patients with κ and λ Chains Multiple Myeloma, Respectively